KITLG / Kit ligand · IHC design guide

Design Immunohistochemistry for KITLG

Plan chromogenic KITLG IHC in paraffin sections using hematopoietic cells in bone marrow as a medium-staining reference (HPA tissue IHC). Interpret cytoplasmic and nuclear tissue staining alongside KITLG’s membrane-bound and soluble forms, and check whether the antibody targets an extracellular or cytoplasmic epitope (HPA tissue IHC; UniProt).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for KITLG (IHC for KITLG): expected localisation Cytoplasmic and nuclear tissue staining (HPA tissue IHC), antibody A01254, validated IHC image, and IHC protocol steps — Printable **KITLG** IHC protocol sheet — expected localisation Cytoplasmic and nuclear tissue staining (HPA tissue IHC), antibody A01254, controls and protocol steps. Open the full KITLG IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

KITLG Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic and nuclear tissue staining (HPA tissue IHC)
	Staining pattern	Leukocytes, marrow and red pulp cells: cytoplasmic/nuclear (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6 HIER, heat-mediated (datasheet A01254)
	Positive control ⓘ	Bone marrow
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Formaldehyde-fixed mouse tissue was used (selected-SKU IHC image A01254); keep fixation consistent (standard IHC practice; not target-specific)
	Caveat	Soluble KITLG can complicate membrane-based interpretation (UniProt)
	Regulation	Expression regulation not established (UniProt)
	Isoform / epitope	3 isoforms; epitope location may affect form detection (UniProt)

Section 1

Recommended KITLG IHC & IF Protocols

Compare the catalog antibody's citrate pH 6 IHC-P protocol (datasheet A01254) with published KITLG staining protocols for PSCC tissue (PMC13457360) and buffalo ovary (PMC10066048).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Formaldehyde-fixed, paraffin-embedded mouse brain tissue (datasheet A01254)
Fixation	Image formalin-fixed; duration unreported (datasheet A01254); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Citrate pH 6 (datasheet A01254); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% serum (datasheet A01254)
Primary antibody	Rabbit anti-KITLG, 2.5 μg/mL (datasheet A01254)
Primary incubation	Overnight at 4 °C (standard)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	KITLG-positive staining in hematopoietic cells of bone marrow (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic and nuclear expression mainly in peripheral leukocytes, hematopoietic cells and cells in splenic red pulp. No signal in the no-primary control.

💡Decision noteStart with heat-mediated citrate pH 6 retrieval (datasheet A01254); the PSCC protocol also uses citrate retrieval without specifying pH (PMC13457360).

Section 2

What Is the Expected KITLG Staining Pattern?

KITLG can occupy the cell membrane, cytoplasm, cell projections and extracellular space; its membrane form has an extracellular region and a cytoplasmic tail (UniProt P21583 topology). In paraffin IHC, expect staining mainly in peripheral leukocytes, hematopoietic cells and splenic red-pulp cells, with cytoplasmic and some nuclear signal reported by HPA (HPA: tissue IHC profile). HPA rates the tissue staining Approved, while noting staining in some cells or structures it has not annotated (HPA: reliability description).

What am I looking at on my slide?
Bone-marrow hematopoietic cells show moderate cytoplasmic staining.	This matches HPA's clearest listed positive tissue and cell population (HPA: bone marrow, hematopoietic cells, Medium). Assess the named cells rather than assigning one score to the entire section; a mixture of stained and unstained cells is more informative than an overall brown appearance (general IHC practice).
Splenic red-pulp cells stain weakly; peripheral leukocytes or hematopoietic cells show cytoplasmic signal, sometimes with nuclear signal.	These findings fit the reported cell distribution, including low staining in splenic red pulp and cytoplasmic and nuclear expression in the broader HPA profile (HPA: spleen, Low; HPA: tissue IHC profile). Nuclear staining alone is therefore not grounds to reject a section; judge its cell distribution and controls (HPA: tissue IHC profile; general IHC practice).
Signal is exclusively nuclear across unrelated cell types, with no convincing staining in the expected populations.	Treat this compartment pattern as a possible artefact and review controls. HPA reports nuclear expression, but mainly in its stated cell populations; UniProt lists membrane, cytoplasmic, projection and secreted locations (HPA: tissue IHC profile; UniProt P21583 subcellular location). Neither source supports calling widespread nuclear-only staining a KITLG-positive result.
Adipocytes or respiratory epithelial cells stain strongly while expected hematopoietic cells remain negative.	Suspect antibody cross-reactivity or endogenous detection activity before interpreting these cells as KITLG positive. HPA lists adipocytes in adipose tissue and respiratory epithelial cells in bronchus as Not detected (HPA: tissue IHC). A negative HPA observation is a comparison point, not proof that every specimen must be negative (general IHC practice).
Brown colour spreads diffusely over cells and surrounding tissue without a discernible cellular pattern.	This is background until it can be separated from cell-associated staining by detection controls and slide review (general IHC practice). KITLG also has a secreted form, so extracellular colour alone cannot identify the producing cell or establish specific ligand staining (UniProt P21583 processing and subcellular location).

💡Expected KITLG appearanceCall a positive IHC result when hematopoietic cells show distinct, predominantly cytoplasmic staining around the Medium level seen in bone marrow; low signal in splenic red-pulp cells is also reported, whereas strong, uniform staining of HPA-negative cell types is suspect (HPA: bone marrow, Medium; HPA: spleen, Low; HPA: tissue IHC negatives).

How each factor affects the staining
Membrane form and epitope location	KITLG residues 26–214 are extracellular, 215–237 span the membrane and 238–273 are cytoplasmic (UniProt P21583 topology). The antibody's epitope is unspecified here, so the record cannot predict whether a given stain will favour membrane, cytoplasmic or released material.
Processing and isoforms	UniProt lists a membrane chain at residues 26–273, a soluble chain at 26–190 and 3 isoforms (UniProt P21583 processing and isoforms). Shedding can complicate attribution of extracellular signal; without an epitope map, do not claim that this antibody detects all forms equally.
Antigen retrieval	The supplied sources give no KITLG-specific retrieval condition or retrieval response. Choose and document a paraffin IHC retrieval condition with a known-positive section, then compare staining and background under that condition (general IHC practice); do not infer fixation sensitivity from HPA staining levels.
Antibody evidence	HPA070395 is Approved for IHC and Uncertain for ICC (HPA: antibody validation). HPA's tissue reliability is also Approved but notes staining in unannotated cells or structures (HPA: reliability description). These ratings support cautious pattern comparison, not an assumption that every stained structure is specific.
IF/ICC Q: where should signal appear?	A: HPA reports vesicles as its approved ICC-IF location (HPA: subcellular summary). This is an IF interpretation clue, not an IHC-P protocol or an upgrade of HPA070395's Uncertain ICC status (HPA: antibody validation).

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
No stain appears in bone-marrow hematopoietic cells.	The expected positive population may be absent from the sampled field, or the IHC detection workflow may have failed; HPA records Medium staining in these cells (HPA: bone marrow, Medium; general IHC practice).	Confirm hematopoietic cells are present, then inspect the positive-control slide and primary-omission control. Review retrieval and detection conditions using the same run before interpreting the specimen as KITLG negative (general IHC practice).
Only faint staining appears in splenic red pulp.	A faint result may match the reported Low level there; it does not by itself show a failed assay (HPA: spleen, Low).	Compare cell-associated signal with local background and the bone-marrow positive reference. Score the red-pulp cells themselves and record the weak intensity rather than increasing the call to a strong positive (HPA: spleen, Low; HPA: bone marrow, Medium; general IHC practice).
Strong colour appears in HPA-listed negative cell types.	Cross-reactivity or endogenous chromogen-generating activity is possible; HPA lists adipose-tissue adipocytes and bronchial respiratory epithelium as Not detected (HPA: tissue IHC negatives; general IHC practice).	Check a primary-omission control and review blocking and detection steps. Reassess whether the colour is cell-specific before assigning a KITLG-positive score (general IHC practice).
The whole section has diffuse brown background.	Nonspecific detection or inadequate blocking can obscure cell boundaries (general IHC practice). KITLG's soluble form also makes an extracellular deposit ambiguous without cell-associated evidence (UniProt P21583 processing).	Compare the primary-omission control, adjust blocking or detection conditions as appropriate, and require a readable cellular distribution before scoring (general IHC practice).
Staining is confined to nuclei throughout the section.	HPA does report nuclear expression mainly in peripheral leukocytes and hematopoietic or splenic red-pulp cells, but widespread nuclear-only staining does not match that qualified profile (HPA: tissue IHC profile).	Identify the stained cell types, compare cytoplasmic signal and controls, and flag a widespread nuclear-only pattern as a possible artefact rather than discarding all nuclear staining (HPA: tissue IHC profile; general IHC practice).
IF/ICC vesicles are visible, but IHC appears weak or different.	HPA describes vesicles in ICC-IF, while its IHC tissue profile describes cytoplasmic and nuclear expression; HPA070395 has different validation ratings for the two applications (HPA: subcellular summary; HPA: tissue IHC profile; HPA: antibody validation).	Interpret each preparation against its own HPA observation and controls. Do not transfer an IF/ICC appearance or protocol into the paraffin IHC decision (HPA: subcellular summary; HPA: tissue IHC profile; general IHC practice).

Source: UniProt P21583 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing KITLG staining

Immunohistochemistry Validation of SCF in Mouse Brain Tissue Immunohistochemical analysis of paraffin-embedded mouse brain tissue using anti-SCF antibody (A01254) at 2.5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 ˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

A01254 · IHCImmunohistochemistry Validation of SCF in Mouse Brain Tissue Immunohistochemical analysis of paraffin-embedded mouse brain tissue using anti

Immunofluorescence Validation of SCF in Human Brain Tissue Immunofluorescent analysis of 4% paraformaldehyde-fixed human brain tissue labeling SCF with A01254 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

A01254 · IFImmunofluorescence Validation of SCF in Human Brain Tissue Immunofluorescent analysis of 4% paraformaldehyde-fixed human brain tissue labeli

M01254 · IHCImmunohistochemical analysis of paraffin-embedded human stomach, using SCF Antibody.

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000049130-KITLG/tissue/cerebral+cortex#imid_19763921

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000049130-KITLG/tissue/colon#imid_19763831

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000049130-KITLG/tissue/liver#imid_19763832

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000049130-KITLG/tissue/kidney#imid_19763833

HPA ICC-IF BJ [Human fibroblast] — KITLG (HPA070395)

HPA · ICC-IF BJ [Human fibroblast]Human Protein Atlas immunofluorescence, BJ [Human fibroblast], antibody HPA070395; green = KITLG, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for KITLG IHC & IF

🧪Run bone marrow first and look for KITLG staining in hematopoietic cells (HPA: Medium in bone marrow hematopoietic cells). Use adipose tissue as the negative tissue (HPA: Not detected in adipocytes); on the bone marrow slide, cells without specific staining should show only the counterstain, but HPA does not identify a particular internal negative cell type.

Positive control tissue: Bone marrow (Hematopoietic cells, HPA Medium)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show KITLG in BJ [Human fibroblast], CACO-2, U2OS, with annotated localisation: Vesicles (approved) (HPA subcellular).

Technical controls: Include a no-primary (secondary-only) slide, an isotype control matched to the primary antibody’s host species and clonality, and KITLG knockout tissue or a validated peptide-block control. Block endogenous peroxidase and check background in bone marrow before interpreting chromogenic staining (standard IHC practice).

⚠️Feasibility: No target-specific fixation window or fixation effect is reported; the A01254 caption mentions formaldehyde, while its structured fixative field says “not stated” (A01254 caption). Heat retrieval in citrate buffer at pH 6 is documented for paraffin-embedded mouse brain, but whether bone marrow staining depends on that retrieval is unreported (A01254 caption). The supplied evidence does not establish that frozen sections or IF are easier; bone marrow background should be assessed with the controls above (standard IHC practice).

HPA tissue IHC evidence for KITLG

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Antibody staining in cells/structures not annotated, view images.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Bone marrow	Hematopoietic cells	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Appendix	Glandular cells	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced KITLG IHC Tips

Troubleshoot chromogenic KITLG staining in paraffin sections by checking retrieval, compartment, cell identity and controls before interpreting signal intensity.

What should I change when KITLG staining is weak after antigen retrieval?

Start with heat-mediated citrate retrieval at pH 6 for paraffin-section IHC (datasheet A01254). The selected image used this retrieval with 2.5 µg/ml primary antibody and an overnight incubation at 4 °C, providing a reference workflow for that specimen and antibody (A01254 tissue-IHC caption). If signal is weak, compare a short and a longer heating interval on matched sections while keeping detection and exposure to chromogen constant (standard IHC practice). If citrate remains ineffective, evaluate another retrieval buffer as a documented fallback, alongside a positive control, because altered staining alone does not establish improved KITLG detection (standard IHC practice).

Could fixation explain weak or uneven KITLG staining?

KITLG-specific sensitivity to fixation is unknown because no comparative fixation evidence is supplied (provided evidence payload). For paraffin sections, record fixative, fixation duration and tissue thickness, then compare matched sections processed together before changing antibody concentration (standard IHC practice). Uneven penetration or prolonged fixation can affect antigen accessibility in general, so check whether weak regions follow tissue thickness or processing boundaries (standard IHC practice). Keep heat-mediated citrate retrieval at pH 6 and the 2.5 µg/ml reference antibody concentration constant during that comparison (datasheet A01254; A01254 tissue-IHC caption). Do not infer fixation sensitivity from the reported tissue staining pattern (HPA tissue IHC).

How should membrane, cytoplasmic and extracellular KITLG staining be evaluated?

Score membrane-associated and cytoplasmic signal separately because KITLG is reported at the cell membrane, in cytoplasm and projections, and as a secreted protein (UniProt P21583 subcellular annotation). Its extracellular region spans residues 26–214, the transmembrane segment 215–237, and the cytoplasmic tail 238–273 (UniProt P21583 topology). A diffuse extracellular deposit therefore needs different interpretation from a cell-associated rim; compare each pattern with cellular morphology and a no-primary control (UniProt P21583 processing; standard IHC practice). Approved vesicular localisation in cellular imaging supports checking punctate intracellular signal, but does not establish its identity in every paraffin section (HPA subcellular).

Why might two KITLG antibodies stain different compartments?

Establish the antibody's immunogen or mapped epitope before comparing staining, because the supplied record lists 3 KITLG isoforms without defining this antibody's epitope (UniProt P21583 isoforms; provided evidence payload). The membrane-associated chain spans residues 26–273, whereas the annotated soluble chain spans 26–190 (UniProt P21583 processing). An epitope in the cytoplasmic tail would exclude the annotated soluble chain; an extracellular epitope could be present in both, subject to antibody validation (UniProt P21583 topology and processing). Seven annotated glycosylation sites and paraffin processing may complicate epitope access, so interpret antibody disagreement with matched controls rather than assigning an isoform from staining alone (UniProt P21583 glycosylation; standard IHC practice).

How can IF help assess whether KITLG and an expected cell marker coincide?

On the separate IF/ICC guide, pair KITLG with a marker chosen for the expected cell population and inspect each channel separately before assessing overlap (standard IF practice). HPA reports KITLG staining mainly in peripheral leukocytes, hematopoietic cells and splenic red-pulp cells, with medium staining in bone-marrow hematopoietic cells (HPA tissue IHC). Choose spectrally separated fluorophores and place the weaker signal in a channel with less specimen autofluorescence, using single-label controls to check bleed-through (standard IF practice). Set permeabilisation according to the mapped epitope: intracellular or cytoplasmic-tail access generally requires it, while an accessible extracellular epitope may not (UniProt P21583 topology; standard IF practice).

What causes widespread brown signal in KITLG chromogenic IHC?

Compare the stained section with no-primary and detection-only controls to locate signal arising from the detection system (standard IHC practice). For an HRP and DAB workflow, block endogenous peroxidase, assess nonspecific secondary binding and keep chromogen development comparable across sections (standard IHC practice). The selected image used 10% serum blocking for 1 hour at room temperature and an HRP secondary at 1:250; these are reported image conditions, not universal optima (A01254 tissue-IHC caption). Because KITLG may be cell associated or secreted, broad brown staining requires morphology and controls before being called extracellular KITLG (UniProt P21583 subcellular annotation; standard IHC practice).

How should KITLG staining be scored across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the compartment and cell population before scoring, then report the percentage of positive cells and an intensity-based H-score using the same thresholds across slides (standard IHC practice). For sparse positive cells, report positive-cell density per mm² within a defined tissue region, alongside the counted area (standard IHC practice). Normalise cell-based measures to eligible cells and area-based measures to analyzable tissue area, excluding folds, edges and necrosis by a prespecified rule (standard IHC practice). Keep membrane, cytoplasmic and extracellular patterns in separate fields because KITLG has membrane-associated and secreted forms (UniProt P21583 processing and subcellular annotation). Include the pH 6 retrieval condition in the methods (datasheet A01254).

When should apparent KITLG positivity be treated as artefact?

Treat staining as more credible when its compartment and cell identity are consistent across intact regions and the no-primary control is clear (standard IHC practice). Membrane, cytoplasmic, projection-associated and extracellular patterns are plausible for KITLG, but a sharply nuclear-only result warrants additional validation against the antibody's epitope and controls (UniProt P21583 subcellular annotation; standard IHC practice). HPA reports cytoplasmic and nuclear staining mainly in peripheral leukocytes, hematopoietic cells and splenic red-pulp cells, so nuclear signal alone cannot settle specificity (HPA tissue IHC). Discount staining confined to cut edges or necrosis, and investigate brown signal persisting without primary antibody as possible endogenous enzyme or detection background (standard IHC practice).

Boster reagents

Best KITLG / Kit ligand IHC Antibodies

The catalog shows KITLG IHC images from mouse brain and human stomach paraffin sections, plus an IF image from human brain (A01254 and M01254 image captions).

Real IHC data

Anti-SCF KITLG Antibody

Cat # A01254

View product →

Real IHC data Immunohistochemical analysis of paraffin-embedded human stomach, using SCF Antibody.

Anti-SCF Rabbit Monoclonal Antibody

Cat # M01254

View product →

A01254 has IHC data from formaldehyde-fixed mouse brain paraffin sections and IF data from paraformaldehyde-fixed human brain (A01254 image captions). M01254 has IHC data from human stomach paraffin sections; its fixative is unreported (M01254 IHC image caption).

Which to pick: For mouse tissue IHC, A01254 has a documented formaldehyde-fixed paraffin-section protocol at 2.5 μg/mL; for human stomach paraffin sections, M01254 has an IHC image, but its fixative is unreported (A01254 and M01254 IHC image captions). For IF, A01254 has human brain data at 20 μg/mL; M01254 lists ICC/IF without an IF image in the payload (A01254 IF image caption; M01254 application list). For work spanning human, mouse and rat, A01254 lists reactivity with all three, though its supplied IHC image validates mouse tissue only (A01254 reactivity list and IHC image caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry P21583 (SCF_HUMAN, Kit ligand).
Human Protein Atlas. KITLG tissue IHC expression (reliability: Approved).
Human Protein Atlas. KITLG subcellular location (ICC-IF): Localized to vesicles..
Human Protein Atlas. KITLG antibody validation summary (1 antibodies).
Single-cell immunoprofiling reveals a dysfunctional-like immune microenvironment and malignant phenotype in aging penile squamous cell carcinoma. Cell biology and toxicology 2026 — PMC13457360.
KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers. Gastroenterology 2015 — PMC4550533.
The potential role of the KFG and KITLG proteins in preventing granulosa cell apoptosis in Bubalus bubalis. Journal, genetic engineering & biotechnology 2023 — PMC10066048.
Regulatory mutations in TBX3 disrupt asymmetric hair pigmentation that underlies Dun camouflage color in horses. Nature genetics 2016 — PMC4731265.
PubMed PMID:2208279 — UniProt-cited evidence.
PubMed PMID:1724381 — UniProt-cited evidence.
PubMed PMID:10049787 — UniProt-cited evidence.